Woodcock Throws Weight Behind Push For New Legislative ‘Substantial Evidence’ Standard For Rare Disease Drugs

 
• By Sarah Karlin-Smith
  
Gold "FDA approved" label
Woodcock said the proposal would not compromise the agency's "gold standard" for drug approvals, but others are less convinced. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Rare Diseases